Dang Shen for Health & Longevity - Quick Reference Sheet

Dang Shen for Health & Longevity

Created on 10/18/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Gemini 4 Argon – Audit

Dang Shen is an East Asian tonic root herb used to support cellular energy, antioxidant defenses, immunity, and respiratory vitality. Human trials show multi-herb oral formulations and intravenous extracts improve lung function, muscle strength, memory, and chemotherapy tolerance, but none test standalone oral Dang Shen. Animal and cell findings show prostate hormone-receptor stimulation, slowed blood clotting, liver enzyme inhibition, and contamination risks, favoring verified sulfur-free extracts. (Full Review)

Protocol

Traditional root decoction or concentrated granules
9–30 g/day dried root
Simmered in water per Chinese Pharmacopoeia; hospital decoctions use 20 g/day
Standardized capsule and clinical regimens
75 mg twice daily (150 mg/day)
Codonopsis pilosula glycosides with food; oncology protocols infuse 250–500 mL/day Shenqi Fuzheng Injection
Single versus split dosing
2–3 divided doses daily
Taken with meals to maintain steady small-molecule plasma levels and minimize gastrointestinal osmotic load
Time to effect
Respiratory Function and Exercise Tolerance
12–24 weeks
COPD spirometry and walk distance (5–10 days for high-altitude ventilatory function)
Muscle Mass, Strength, and Glycemic Control in Sarcopenia
12 weeks
Skeletal muscle mass, handgrip strength, chair-stand speed, CRP, and fasting blood glucose
Endothelial Function, Vascular Inflammation, and Lipid Peroxidation
6 weeks
Vascular and antioxidant shifts in hs-CRP, malondialdehyde, and serum nitrite

Benefits

Contraindications
  • Men with prostate cancer or prostatic intraepithelial neoplasia (particularly those treated with abiraterone acetate or androgen receptor antagonists)
  • Pregnant or lactating women
  • Severe hepatic or renal impairment (ALT or AST > 2.5× ULN, serum creatinine > 1.5× ULN)
  • Uncontrolled hypertension (SBP > 160 mmHg or DBP > 100 mmHg), NYHA Class III–IV heart failure, hypotension (SBP < 80 mmHg), or active bleeding
  • Severe thrombocytopenia (platelets < 75 × 109/L) or active interstitial lung disease
Key Interactions
  • Androgen receptor antagonists and steroidogenesis inhibitors (abiraterone acetate, enzalutamide, apalutamide; theoretical)
  • Narrow-therapeutic-index CYP3A4 substrates (cyclosporine, tacrolimus, midazolam, simvastatin, irinotecan; theoretical)
  • Prescription anticoagulants and antiplatelets (warfarin, apixaban, rivaroxaban, clopidogrel; theoretical)
  • Over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs: aspirin, ibuprofen, naproxen; theoretical)
  • Anticoagulant or antiplatelet supplements (Ginkgo biloba, Salvia miltiorrhiza, garlic, marine omega-3 fatty acids; theoretical)
  • Blood-pressure- or glucose-lowering supplements and drugs (losartan, amlodipine, metformin, berberine, Astragalus membranaceus)
  • Scheduled surgical procedures and general anesthesia (at least 14 days before elective surgery; theoretical)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Mild gastrointestinal upset, dry mouth, and insomnia; respiratory and hepatobiliary adverse events in pulmonary fibrosis; parenteral infusion and hypersensitivity reactions
  • Speculative: Antagonism of androgen-deprivation therapy in prostate cancer; cytochrome P450 3A4 inhibition; platelet inhibition and prolonged coagulation time; appetite and weight suppression from sulfur-fumigated roots; exposure to pesticide residues, cadmium, and botanical adulterants

Monitoring

Marker Target Why
Resting Blood Pressure (SBP / DBP) No established target; track change from individual baseline Expected to change (efficacy) & safety check; measured seated in the morning after 5 minutes of rest
High-Sensitivity C-Reactive Protein (hs-CRP) 0.0–3.0 mg/L (standard reference range) Expected to change (efficacy); drawn fasting in the absence of acute infection
Fasting Blood Glucose (FBG) 70–99 mg/dL (standard reference range) Expected to change (efficacy); 8–12 hour overnight fast required
Complete Blood Count (CBC) with Differential WBC 4.5–11.0 × 109/L; Platelets 150–400 × 109/L (standard reference range) Expected to change (efficacy) & safety check; tracks leukocyte/lymphocyte support and screens for rare thrombocytopenia
Liver Transaminases (ALT, AST) ALT 7–56 U/L; AST 8–33 U/L (standard reference range) Safety check; screens for herbal adulterant or pesticide hepatotoxicity (trial exclusion > 2.5× ULN)
Coagulation Panel (PT / INR) INR 0.8–1.1 (standard reference range) Safety check; monitors for prolonged clotting time from platelet/coagulation inhibition, especially with antithrombotics
Total Prostate-Specific Antigen (PSA) 0.0–4.0 ng/mL (standard reference range) Safety check; monitored in men over 40 due to preclinical androgen receptor upregulation (drawn after 48 hours without ejaculation)

Cadence: Baseline assessment (laboratory panel, seated morning blood pressure, and handgrip dynamometry) before initiation; safety blood tests (ALT, AST, CBC, and PT/INR) repeated at 4 weeks after initiation; all efficacy and safety biomarkers re-evaluated at 12 weeks and every 6 months thereafter during cyclical supplementation.

Qualitative Assessment

  • Physical performance: Objective functional tracking uses six-minute walk distance (6MWD), handgrip strength, and five-time chair stand speed at baseline and week 12.
  • Vitality and breathing: Subjective logs track daily fatigue, post-exercise recovery, and exertional breathlessness.
  • Digestive and hemostatic tolerance: Tolerance tracking records stool consistency, appetite, and any unexplained bruising.